Jmac Enterprises LLC Acquires New Shares in Becton, Dickinson and Company (NYSE:BDX)

Jmac Enterprises LLC acquired a new position in Becton, Dickinson and Company (NYSE:BDX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 2,121 shares of the medical instruments supplier’s stock, valued at approximately $481,000.

Several other hedge funds and other institutional investors have also bought and sold shares of BDX. CWM LLC boosted its holdings in Becton, Dickinson and Company by 0.6% in the third quarter. CWM LLC now owns 8,965 shares of the medical instruments supplier’s stock worth $2,161,000 after purchasing an additional 57 shares during the last quarter. Sound Income Strategies LLC boosted its stake in shares of Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares during the last quarter. Paladin Wealth LLC bought a new stake in shares of Becton, Dickinson and Company in the third quarter worth $150,000. ORG Wealth Partners LLC bought a new stake in shares of Becton, Dickinson and Company in the third quarter worth $240,000. Finally, CX Institutional increased its position in Becton, Dickinson and Company by 128.6% during the third quarter. CX Institutional now owns 1,175 shares of the medical instruments supplier’s stock valued at $283,000 after acquiring an additional 661 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Piper Sandler boosted their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, January 28th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $283.00.

Becton, Dickinson and Company Trading Down 0.0 %

Shares of NYSE:BDX opened at $229.50 on Wednesday. The stock has a 50 day moving average of $232.20 and a 200 day moving average of $233.99. The company has a market cap of $66.56 billion, a PE ratio of 38.12, a price-to-earnings-growth ratio of 1.65 and a beta of 0.40. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $251.99. The company has a current ratio of 1.13, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. As a group, equities research analysts expect that Becton, Dickinson and Company will post 14.41 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be issued a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 1.81%. Becton, Dickinson and Company’s dividend payout ratio is presently 69.10%.

Becton, Dickinson and Company declared that its board has authorized a stock repurchase plan on Tuesday, January 28th that permits the company to buyback 10,000,000 shares. This buyback authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board of directors believes its stock is undervalued.

Insider Activity

In related news, Director Jeffrey William Henderson bought 1,500 shares of the stock in a transaction dated Monday, February 10th. The shares were purchased at an average price of $233.62 per share, with a total value of $350,430.00. Following the completion of the acquisition, the director now owns 8,015 shares of the company’s stock, valued at $1,872,464.30. This represents a 23.02 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Roland Goette sold 4,483 shares of the firm’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $221.01, for a total transaction of $990,787.83. Following the transaction, the executive vice president now directly owns 24,345 shares of the company’s stock, valued at $5,380,488.45. The trade was a 15.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 9,844 shares of company stock worth $2,210,716 over the last ninety days. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.